Other strategic therapeutic areas include renal bone disease, also resulting from vitamin D research, and anticoagulation, in particular heparin, both unfractionated and low molecular weight products.
For additional information or comments, please contact:
LEO Pharma
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/menuHome.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/menuIndicator2.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/topOfLeftMenu.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/print.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/h_line.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/top.gif){kind=small}
/(E100A3479E2D2A0D9B0B186CE59A1ABD)/$File/dotted_line.gif){kind=small}
Sitemap